Dyslipidemia and therapies after heart transplantation: Current evidence and future directions - PubMed
5 hours ago
- #Dyslipidemia
- #Heart Transplant
- #Immunosuppressive Therapy
- Dyslipidemia affects up to 80% of heart transplant recipients, contributing to cardiovascular disease and graft failure.
- Post-transplant dyslipidemia arises from traditional risk factors and immunosuppressive medications.
- Statins are the primary treatment, reducing graft vasculopathy and mortality, but require careful dosing due to drug interactions.
- Nonstatin therapies vary in suitability, with some showing promise but others posing interaction risks.
- Emerging therapies like bempedoic acid and siRNA therapeutics show potential but need further research.
- Individualized treatment strategies are essential, considering drug interactions and long-term outcomes.
- Future research should focus on optimal LDL-C targets and novel lipid-lowering agents.